NICE okays regular NHS funding for Novartis’ breast cancer drug KisqaliNICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously Share XNICE okays regular NHS funding for Novartis’ breast cancer drug Kisqalihttps://pharmaphorum.com/news/nice-okays-regular-nhs-funding-for-novartis-breast-cancer-drug-kisqali/
Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
MacroGenics’ HER2 breast cancer drug Margenza approved in USMacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with Share XMacroGenics’ HER2 breast cancer drug Margenza approved in UShttps://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerDaiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) Share XDaiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerhttps://pharmaphorum.com/news/daiichi-sankyo-az-close-on-eu-approval-of-enhertu-for-breast-cancer/
Merck & Co buys cancer biotech VelosBio for $2.75bnMerck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion Share XMerck & Co buys cancer biotech VelosBio for $2.75bnhttps://pharmaphorum.com/news/merck-co-buys-cancer-biotech-velosbio-for-2-75bn/
ANGLE raises £20m, eyes opportunity in immunotherapy trialsLiquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will Share XANGLE raises £20m, eyes opportunity in immunotherapy trialshttps://pharmaphorum.com/news/angle-raises-20m-eyes-opportunity-for-parsortix-in-immunotherapy-trials/
Toxic positivity and grief: The reality of living through cancerCancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient Share XToxic positivity and grief: The reality of living through cancerhttps://pharmaphorum.com/views-analysis-patients/toxic-positivity-and-grief-the-reality-of-living-through-cancer/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
Immunomedics wows ESMO with breast cancer data revealImmunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover, after the biotech’s Share XImmunomedics wows ESMO with breast cancer data revealhttps://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/
